Autoantibodies against type I IFNs in patients with critical influenza pneumonia
0301 basic medicine
Informe de Investigación
Virus de la Influenza A
SEVERE COVID-19
Pneumònia
DETERMINANTS
Autoanticossos
Settore MED/03 - GENETICA MEDICA
Virus Replication
3C-Dijon Study
03 Salud y bienestar
INFECTION
Medicine and Health Sciences
Prevalence
MYASTHENIA-GRAVIS PATIENTS
REIPI INF Working Group
Yellow Fever Vaccine
Autoanticuerpos
Influenza A virus
Influenza Vaccines
Interferon Type I
[SDV.IMM]Life Sciences [q-bio]/Immunology
BURDEN
Constances Cohort
INTERFERON
Cerba HealthCare Group
Anticuerpos
SARS-Cov-2
610
IMMUNITY
Antibodies
Article
NEUTRALIZING ANTIBODIES
Grip
Vacuna contra la Fiebre Amarilla
03 medical and health sciences
616
Neumonía
Influenza, Human
[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]
Gripe Humana
Type I interferons
Interferón Tipo I
Humans
COVID Human Genetic Effort
320505 Enfermedades infecciosas
Autoantibodies
Células A549
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics
Etablissement Français du Sang Study Group
COVID-19
Pneumonia
ALLELES
Lyon Antigrippe Working Group
Influenza
ALPHA
A549 Cells
03 Good Health and Well-being
32 Ciencias médicas
DOI:
10.1084/jem.20220514
Publication Date:
2022-09-16T14:15:36Z
AUTHORS (244)
ABSTRACT
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (88)
CITATIONS (75)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....